Allergen-Specific Immunotherapy

At least a moderate level of evidence exists to support the use of allergen-specific immunotherapy as a safe and effective treatment for nasal allergies and mild asthma in adults and children, according to a new AHRQ research review, Allergen-Specific Immunotherapy for the Treatment of Allergic Rhinoconjunctivitis and/or Asthma. The review’s findings also appeared in the March 27 issue of the Journal of the American Medical Association (JAMA). The immunotherapy was either injected under the skin (subcutaneous) or placed under the tongue (sublingual).

Go to: http://www.effectivehealthcare.ahrq.gov